Your browser is no longer supported. Please, upgrade your browser.
Settings
CYTR CytRx Corporation daily Stock Chart
CYTR [NASD]
CytRx Corporation
Index- P/E- EPS (ttm)-1.12 Insider Own1.20% Shs Outstand28.44M Perf Week-4.01%
Market Cap37.40M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float23.62M Perf Month-19.82%
Income-28.00M PEG- EPS next Q-0.25 Inst Own8.10% Short Float8.51% Perf Quarter-17.81%
Sales0.10M P/S373.99 EPS this Y61.50% Inst Trans-6.42% Short Ratio5.10 Perf Half Y-34.90%
Book/sh0.78 P/B1.69 EPS next Y- ROA-56.10% Target Price24.00 Perf Year-56.54%
Cash/sh1.23 P/C1.07 EPS next 5Y- ROE-139.90% 52W Range1.24 - 5.99 Perf YTD-22.19%
Dividend- P/FCF- EPS past 5Y20.90% ROI-114.50% 52W High-78.04% Beta1.97
Dividend %- Quick Ratio1.90 Sales past 5Y0.00% Gross Margin- 52W Low6.05% ATR0.10
Employees20 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)36.95 Volatility3.38% 5.48%
OptionableYes Debt/Eq0.47 EPS Q/Q74.50% Profit Margin- Rel Volume0.45 Prev Close1.32
ShortableYes LT Debt/Eq0.00 EarningsMay 09 Payout- Avg Volume394.22K Price1.32
Recom2.00 SMA20-17.31% SMA50-21.18% SMA200-36.75% Volume176,468 Change-0.38%
Jul-12-16Reiterated FBR Capital Outperform $8 → $3
Jan-07-16Initiated Jefferies Hold
Apr-17-15Initiated Oppenheimer Outperform $10
Jan-23-14Reiterated Aegis Capital Buy $9 → $12
Jan-08-14Reiterated Aegis Capital Buy $8 → $9
Dec-12-13Reiterated Aegis Capital Buy $7 → $8
Dec-04-12Initiated Aegis Capital Buy $8
Sep-10-12Initiated Rodman & Renshaw Mkt Outperform $7
Jan-08-10Initiated Roth Capital Buy $2
Dec-03-09Initiated Merriman Buy
Jun-08-09Initiated Rodman & Renshaw Mkt Outperform $2
Mar-03-09Reiterated Brean Murray Buy $3 → $2
Jun-12-08Initiated Brean Murray Buy $3
Jan-23-08Reiterated Broadpoint Capital Buy $8 → $6.50
Oct-24-07Initiated Broadpoint Capital Buy $8
Oct-19-07Initiated Oppenheimer Buy $6
Apr-05-07Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-17-18 09:00AM  CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting PR Newswire
May-15-18 04:44PM  CytRx Announces Closing of $7.0 Million Registered Direct Offering PR Newswire
May-11-18 08:00AM  CytRx Announces $7.0 Million Registered Direct Offering PR Newswire -32.80%
May-08-18 09:26AM  CytRx: 1Q Earnings Snapshot Associated Press
08:30AM  CytRx Reports First Quarter 2018 Financial Results PR Newswire
May-07-18 09:00AM  CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018 PR Newswire +5.00%
May-03-18 08:30AM  CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer PR Newswire
Apr-30-18 09:00AM  CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting PR Newswire
Apr-18-18 08:00AM  CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting PR Newswire -7.29%
Apr-09-18 09:00AM  CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR Drug Candidates at the AACR 2018 Conference PR Newswire
Mar-28-18 05:36PM  Edited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMT Thomson Reuters StreetEvents
07:10AM  Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment ACCESSWIRE
Mar-19-18 07:00AM  CytRx Corporation to Host Earnings Call ACCESSWIRE -15.17%
06:19AM  CytRx reports 4Q loss Associated Press
05:30AM  CytRx Reports 2017 Financial Results PR Newswire
Mar-16-18 09:00AM  CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference PR Newswire +11.64%
Mar-15-18 09:00AM  CytRx Selects Four New LADR Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials PR Newswire
Mar-12-18 09:00AM  CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018 PR Newswire
Mar-05-18 09:00AM  CytRx to Present at the 30th Annual ROTH Conference PR Newswire
Mar-02-18 05:47PM  Are Earnings Prospects Improving For Loss-Making CytRx Corporations (NASDAQ:CYTR)? Simply Wall St. +7.79%
Mar-01-18 09:00AM  CytRx Announces Key Addition to Corporate Development Team PR Newswire
Feb-28-18 09:00AM  CytRx Announces Expansion of Pharma Partnering Activities for Its LADR Ultra-High Potency Drug Candidates PR Newswire
Feb-22-18 09:00AM  CytRx Announces the Presentation of New LADR Candidate Data at the American Association for Cancer Research 2018 Annual Meeting PR Newswire
Feb-06-18 09:00AM  CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference PR Newswire
Feb-05-18 09:00AM  CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma PR Newswire
Jan-24-18 08:10AM  Todays Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx Corporation ACCESSWIRE -11.89%
Jan-17-18 09:00AM  CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer PR Newswire
Jan-03-18 09:00AM  CytRx Corporation to Present at Biotech Showcase 2018 PR Newswire
Dec-07-17 09:00AM  CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences PR Newswire
Dec-06-17 09:00AM  CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR Drug Candidates PR Newswire
Nov-27-17 09:00AM  CytRx Corporation to Present at Upcoming Investor Conferences PR Newswire
Nov-20-17 08:00AM  Todays Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation ACCESSWIRE
Nov-17-17 09:00AM  CytRx Corporation Regains Nasdaq Listing Compliance PR Newswire +7.98%
Nov-13-17 09:00AM  CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives PR Newswire
Nov-08-17 09:29AM  CytRx reports 3Q loss Associated Press
09:00AM  CytRx Reports Third Quarter 2017 Financial Results PR Newswire
Nov-07-17 07:53AM  Is CytRx Corporations (CYTR) Balance Sheet A Threat To Its Future? Simply Wall St. -8.53%
Nov-06-17 09:00AM  CytRx Announces Strategic Realignment of Clinical Development Team PR Newswire
Nov-02-17 09:00AM  CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline PR Newswire +5.24%
08:20AM  Today's Research Reports on Stocks to Watch: CytRx Corporation and Skyline Medical ACCESSWIRE
Oct-31-17 09:00AM  CytRx Corporation Announces Reverse Stock Split PR Newswire +10.23%
Oct-27-17 02:15PM  CytRx Corporation Announces Results from Special Meeting of Stockholders PR Newswire -5.56%
Oct-24-17 04:45PM  Lifshitz & Miller LLP Announces Investigation of Antares Pharma, Inc., CenturyLink, Inc., CytRx Corporation, Dentsply Sirona, Inc., Dr. Reddy's Laboratories Limited, J.Jill, Inc., and Navient Corporation PR Newswire
Oct-16-17 06:23PM  CytRx Corporation Announces Outcome of Nasdaq Hearing PR Newswire
Oct-12-17 09:00AM  CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc. PR Newswire
Oct-04-17 09:30AM  Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm PR Newswire -8.00%
09:00AM  Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split PR Newswire
Oct-02-17 09:00AM  CytRx Corporation Provides Business Update and Highlights Future Plans PR Newswire
Sep-21-17 09:00AM  Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split PR Newswire
Sep-13-17 09:00AM  CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting PR Newswire
Aug-30-17 09:00AM  CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting PR Newswire
Aug-24-17 09:00AM  CytRx Corporation Announces Receipt of NASDAQ Listing Determination PR Newswire -6.04%
Aug-21-17 09:00AM  CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting PR Newswire
Aug-10-17 08:00AM  CytRx New Drug Development Agreement Brings Cash and Experience ACCESSWIRE
Aug-04-17 03:11AM  CytRx reports 2Q loss Associated Press -6.18%
Aug-03-17 09:00AM  CytRx Reports Second Quarter 2017 Financial Results PR Newswire -15.64%
Aug-01-17 01:08PM  4 Biotech Stocks to Watch This Quarter GuruFocus.com -15.16%
Jul-31-17 08:20AM  Today's Research Reports on Stocks to Watch: CytRx Corporation and ImmunoGen ACCESSWIRE +17.87%
Jul-28-17 09:00AM  CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic PR Newswire +43.61%
Jun-30-17 04:01PM  Penny Stocks to Watch for June 2017 (CYTR, DELT) Investopedia -8.25%
Jun-13-17 09:00AM  CytRx Announces Reshaping of Clinical and Regulatory Executive Team PR Newswire +5.05%
Jun-09-17 08:00AM  Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation Accesswire -5.57%
Jun-08-17 09:00AM  CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas PR Newswire +13.64%
Jun-05-17 11:55PM  Goodbye CytRx, Your Game Is Over TheStreet.com -33.02%
May-31-17 09:46AM  Penny Stocks to Watch for June 2017 Investopedia
08:00AM  Today's Research Reports on Stocks to Watch: Endocyte and CytRx Accesswire
May-19-17 08:21AM  The Most Notable Abstracts Released Ahead Of ASCO 2017 Benzinga
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx Accesswire
May-17-17 05:04PM  CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting PR Newswire +7.80%
May-10-17 09:28AM  CytRx reports 1Q loss Associated Press
09:00AM  CytRx Reports First Quarter 2017 Financial Results PR Newswire
Apr-28-17 07:51AM  CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock PR Newswire -25.69%
Apr-27-17 05:55PM  CytRx Corporation Announces Proposed Public Offering of Common Stock PR Newswire -15.02%
Apr-21-17 09:00AM  CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO) PR Newswire +21.87%
Apr-20-17 06:07PM  CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up Zacks
02:16PM  ETFs with exposure to CytRx Corp. : April 20, 2017 Capital Cube
08:15AM  Blog Coverage CytRx Announces FDA's Approval for New Drug Application Accesswire
Apr-19-17 07:00AM  CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas PR Newswire +18.18%
Apr-11-17 01:46PM  For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1 TheStreet.com
Apr-07-17 04:20PM  ETFs with exposure to CytRx Corp. : April 7, 2017 Capital Cube
Mar-27-17 03:54PM  ETFs with exposure to CytRx Corp. : March 27, 2017 Capital Cube
03:54PM  ETFs with exposure to CytRx Corp. : March 27, 2017
Mar-21-17 01:04PM  CYTRX CORP Financials
09:25AM  CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
09:25AM  CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-15-17 09:22AM  CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition
09:00AM  CytRx Reports 2016 Financial Results PR Newswire
Mar-08-17 12:40PM  The 'Gnarly 9' Biotechs Will Test the FDA's Mettle TheStreet.com
12:40PM  [video]The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
10:26AM  The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
Mar-07-17 09:00AM  CytRx to Present at the 29th Annual ROTH Conference PR Newswire
Feb-24-17 05:14PM  CYTRX CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
Feb-06-17 09:00AM  CytRx to Present at the 19th Annual BIO CEO & Investor Conference PR Newswire
Jan-13-17 04:47PM  CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers
Jan-06-17 05:01PM  CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers
Jan-04-17 09:00AM  CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas PR Newswire
Dec-30-16 08:50AM  Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock? Zacks
Dec-19-16 05:11PM  CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers -6.97%
09:00AM  CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer PR Newswire
Dec-14-16 05:18PM  CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws;
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.